A5052853562- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Single-cell and spatial transcriptomics
- Viral-associated cancers and disorders
- Renal cell carcinoma treatment
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Lung Cancer Treatments and Mutations
- Eosinophilic Esophagitis
- Neutropenia and Cancer Infections
- Breast Lesions and Carcinomas
- Cancer and Skin Lesions
- Machine Learning in Healthcare
- Breast Cancer Treatment Studies
- Mesenchymal stem cell research
- Cytomegalovirus and herpesvirus research
- Cardiomyopathy and Myosin Studies
- Digital Imaging for Blood Diseases
- Cerebrospinal fluid and hydrocephalus
- Celiac Disease Research and Management
- Glycosylation and Glycoproteins Research
Memorial Sloan Kettering Cancer Center
2013-2023
UCSF Helen Diller Family Comprehensive Cancer Center
2022
University of California, San Francisco
2022
Mount Sinai Medical Center
2007
BACKGROUND. Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis cfDNA Examine Somatic Status), an NGS assay for detection very low frequency alterations in 129 genes. Analytical validation demonstrated 92% sensitivity de-novo mutation calling down 0.5% allele and 99% a priori profiling. To evaluate the performance MSK-ACCESS, report results 681 prospective...
Clinical trial matching is a key process in health delivery and discovery. In practice, it plagued by overwhelming unstructured data unscalable manual processing. this paper, we conduct systematic study on scaling clinical using large language models (LLMs), with oncology as the focus area. Our grounded system currently test deployment at U.S. network. Initial findings are promising: out of box, cutting-edge LLMs, such GPT-4, can already structure elaborate eligibility criteria trials...
BACKGROUND Successful peripheral blood stem cell transplantation (PBSCT) depends on the collection and infusion of adequate numbers progenitor cells (PBPCs). Several predictors PBPC yield are used currently, including white (WBC) count CD34 analysis. This study evaluated utility new automated hematopoietic available Sysmex XN hematology analyzers (XN‐HPCs) in PBSCT. STUDY DESIGN AND METHODS The performance characteristics XN‐HPC, CD34+, WBC analysis were compared using 107 matched apheresis...
BACKGROUND Allogeneic hematopoietic stem cell donor selection is based primarily on human leukocyte antigen degree of match and it often occurs without regard to the red blood (RBC) compatibility between recipient. When major ABO‐mismatched grafts are infused, imperative that an accurate determination incompatible RBC content made ensure product safe for infusion. requires hematocrit (Hct) parameter which can be obtained via manual (directly measured) or automated (calculated) methods. STUDY...
Abstract Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable. We have developed and clinically implemented MSK-ACCESS (Analysis cfDNA Evaluate Somatic Status), an NGS assay for detection very low frequency in select exons introns 129 genes. Analytical validation demonstrated 92% sensitivity de-novo mutation calling down 0.5% allele 98% a priori profiling. To evaluate...
Abstract Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable. We have developed and clinically implemented MSK-ACCESS (Analysis cfDNA Evaluate Somatic Status), an NGS assay for detection very low frequency in select exons introns 129 genes. Analytical validation demonstrated 92% sensitivity de-novo mutation calling down 0.5% allele 99% a priori profiling. To evaluate...
Abstract Background: As the repertoire of molecular targeted therapies for hematologic malignancies continues to expand, so too does opportunity profiling inform treatment decisions. While mutations in certain genes, such as JAK2, MPL, MYD88 and BRAF have diagnostic utility, others FLT3, NPM1, IDH1, IDH2, DNMT3A, KIT CEBPA prognostic value. Here, we present development clinical experience MSK-IMPACT Heme (Integrated Mutation Profiling Actionable Cancer Targets Hematologic malignancies), a...
Background:As the repertoire of molecular targeted therapies for hematologic malignancies continues to expand, so too does opportunity profiling inform treatment decisions. While mutations in certain genes, such as JAK2, MPL, MYD88 and BRAF have diagnostic utility, others FLT3, NPM1, IDH1, IDH2, DNMT3A, KIT CEBPA prognostic value. Here, we present development clinical experience MSK-IMPACT Heme (Integrated Mutation Profiling Actionable Cancer Targets Hematologic malignancies), a...
A 14-yr-old male, weighing 60 kg, with hypertrophic cardiomyopathy (HCM) of unknown etiology and severe biventricular dysfunction presented for orthotopic heart transplantation. Intraoperative transesophageal echocardiography (TEE) was used before after discontinuation cardiopulmonary bypass (CPB) to guide hemodynamic management. pulmonary artery catheter not inserted as per our institutional protocol pediatric TEE Doppler interrogation the tricuspid valve regurgitation estimate right-sided...